What has caused the sharp increase in respiratory medicine sales in India?

The sale of medicines for respiratory ailments increased sharply between 2024 and 2025, with experts and the government citing air pollution as a major triggering factor.

What is the government's stance on air pollution and respiratory illnesses?

The government stated that air pollution is a major triggering factor for respiratory illnesses, though it noted there is no conclusive data to establish a direct correlation exclusively due to air pollution.

What do public health experts recommend regarding respiratory health in India?

Public health experts recommend stronger air quality controls and long-term preventive public health measures to reduce the underlying causes of respiratory illness.

Home / Health / Respiratory Illness Soars: Drug Sales Spike Over ₹1700 Cr

Respiratory Illness Soars: Drug Sales Spike Over ₹1700 Cr

11 Feb

•

Summary

Respiratory medicine sales increased by over ₹1700 crore from 2024 to 2025.
Government cites air pollution as a major trigger for respiratory illnesses.
Experts urge stronger air quality controls and preventive health measures.

Respiratory Illness Soars: Drug Sales Spike Over ₹1700 Cr

Sales of medicines treating respiratory ailments saw a substantial increase from 2024 to 2025. Data from the NPPA indicates a rise of over ₹1700 crore in the total sales value of respiratory system medicines in December alone. This surge reflects a growing demand for drugs addressing conditions like asthma, COPD, and allergies.

The government has identified air pollution as a primary trigger for respiratory illnesses. While acknowledging the lack of conclusive data directly linking air pollution solely to deaths or diseases, it recognizes it as a significant contributing factor. Health experts highlight that a combination of factors, including lifestyle and environmental influences, synergistically impacts respiratory health.